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 BACKGROUND AND OBJECTIVES 
 METHODS 
 RESULTS & DISCUSSION 
 CONCLUSIONS AND FUTURE RESEARCH 
• The risk of venous thromboembolism (VTE) in major orthopaedic surgery is among the highest for all surgical specialties, and can result in significant 
morbidity and mortality(1).  
• Since its inclusion in the American College of Chest Physicians guidelines (1)  and the 2018 NICE guidelines(2) , aspirin has gained interest as an alternative 
to low-molecular-weight heparin (LMWH) or oral anticoagulants, although the evidence for its use is still emerging. Rates of major bleeding, wound 
complications and infection may be lower with aspirin than with oral anticoagulants or LMWH(3). 
• The aim of the study was to establish whether the extended aspirin regimen (a multimodal aspirin regimen) is appropriate for thromboprophylaxis in 
our patient population by comparing it to two other regimens: the inpatient enoxaparin regimen and the modified rivaroxaban regimen. 
• This was a retrospective cohort study, and an extension of a previous study carried out in Cappagh National Orthopaedic Hospital (CNOH).  
• Ethical approval was granted by CNOH Ethics Committee.  
• Data were collected from Bluespier, the hospital’s electronic patient record database. 6,548 patients undergoing elective primary total hip or knee 
replacement (THR or TKR respectively) between 1st January 2010 and 30th June 2016, and who attended their six-month review with the CNOH Joint 
Register, were included.  
• Outcome: Pre-discharge VTE recorded as an inpatient complication by a clinician, or post-discharge VTE reported at the six-month Joint Register review. 




• Demographics: Of the 6,548 patients, 56% underwent THR, 55% were female, 57% were aged ≥65 years, 52% had a body mass index of ≥30kg/m2. 
These were similar to demographics reported in other studies and registries. 5% had a history of VTE, higher than reported elsewhere, indicating that 
our patients may have had a higher overall VTE risk than those in similar studies and registries. 36% were taking a regular antiplatelet or anticoagulant.  
• The overall VTE rate in the study population was  0.99%, lower than rates reported in other studies and registries. 
• There was no statistically significant difference between the  VTE rate in extended aspirin group and the two comparator groups. The VTE rate was 
0.38% lower in the modified rivaroxaban group compared to the extended aspirin group , less than the clinically significant difference of 1%. VTE 








      Other regimens n=785; Data missing n=130 
 
• The treatment groups were demographically well matched overall. Length of stay was shortest in the extended aspirin group and longest in the 
inpatient enoxaparin group (mode 3 vs. 7 days, median 4 vs. 7 days). This reflects advances in post-operative management and rehabilitation over the 
course of the study, allowing earlier discharge. This was a possible confounding factor between these two groups. 
• A prior history of  VTE was a statistically and clinically significant risk factor for post-operative VTE (0.87% vs. 3.54%, p=0.0002). 
• Undergoing TKR, older age, female gender, obesity, and regular use of anticoagulant or antiplatelet agents were associated with a higher VTE risk, but 
these risk factors were not statistically significant.  
THROMBOPROPHYLAXIS REGIMEN VTE RATE 
Extended aspirin regimen (n=3,460)  1.04% 
Inpatient enoxaparin regimen (n=961)  1.04% 
Modified rivaroxaban regimen (n=1,212)  0.66% (p=0.154) 
• These findings have implications locally in confirming the efficacy of our current standard thromboprophylaxis regimen, and the results are considered 
generalisable to patients undergoing elective primary THR or TKR nationally and internationally.  
• This study adds to the growing evidence supporting the use of aspirin for thromboprophylaxis in the orthopaedic setting, although further randomised 
controlled trials comparing aspirin to low-molecular-weight heparin are needed to fully establish its role. 
• Future research in CNOH should investigate the risk of bleeding and wound complications with this regimen, as well as the impact of weight-adjusted 
dosing of enoxaparin for patients weighing ≥100kg(4) introduced in 2017. 
Enoxaparin 40mg commenced 12 hours 
post-surgery 
Continue enoxaparin 40mg daily until 
discharge 
Inpatient enoxaparin regimen 2010 
Continue enoxaparin 40mg 
daily for a total of three doses 
Switch to aspirin 150mg daily for 28 days 
Extended aspirin regimen 2013-Present 
Switch to rivaroxaban 10mg daily for 14 days 
(TKR) or 35 days (THR) 
Modified rivaroxaban regimen 2011-2013* 
Figure 1: Description and Timeline of Standard Thromboprophylaxis Regimens in CNOH 
*Rivaroxaban (as per 
Summary of Product 
Characteristics) trialled  in 
2010. Protocol modified due 
to post-operative bleeding 
and wound complications. 
